{"id":"NCT02973087","sponsor":"Takeda","briefTitle":"rVWF IN PROPHYLAXIS","officialTitle":"A PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-16","primaryCompletion":"2020-07-06","completion":"2020-07-06","firstPosted":"2016-11-25","resultsPosted":"2021-08-06","lastUpdate":"2021-08-06"},"enrollment":29,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Von Willebrand Disease"],"interventions":[{"type":"BIOLOGICAL","name":"von Willebrand factor (Recombinant)","otherNames":["BAX 111","rVWF","VONVENDI","vonicog alfa","BAX111"]},{"type":"BIOLOGICAL","name":"Antihemophilic Factor (Recombinant)","otherNames":["ADVATE","Recombinant Factor VIII","rFVIII"]}],"arms":[{"label":"All Study Participants","type":"EXPERIMENTAL"}],"summary":"The purpose of this phase 3 study is to investigate the efficacy and safety, including immunogenicity, thrombogenicity and hypersensitivity reactions, as well as pharmacokinetics (PK), health related quality of life (HRQoL) and pharmacoeconomics of prophylactic treatment with recombinant von Willebrand factor (rVWF) (vonicog alfa) in adult participants with severe von Willebrand disease (VWD).","primaryOutcome":{"measure":"Ratio of Annualized Bleeding Rate (ABR) for Spontaneous Bleeding Episodes (BEs) (On-study ABR / Historical ABR) Assessed by Investigator During Prophylactic Treatment With rVWF Through Month 12","timeFrame":"Up to 12 months","effectByArm":[{"arm":"Prior On-demand Participants","deltaMin":0.085,"sd":null},{"arm":"Switch Participants","deltaMin":0.55,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["United States","Canada","France","Germany","Italy","Netherlands","Russia","Spain","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["36861346","35439298"],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b5fc34db2bf003ab45955"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":13},"commonTop":["Headache","Arthralgia","Ear infection","Gastroenteritis","Joint injury"]}}